Search Results - Werner Scheithauer

Refine Results
  1. 1
    Clinical trials of agents that reverse multidrug resistance. A literature review

    Clinical trials of agents that reverse multidrug resistance. A literature review by Markus Raderer, Werner Scheithauer

    Published 1993
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    Ondansetron for Pruritus Due to Cholestasis

    Ondansetron for Pruritus Due to Cholestasis by Markus Raderer, Christian A. Müller, Werner Scheithauer

    Published 1994
    Get full text Get full text
    Carta
    Save to List
    Saved in:
  3. 3
    MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside

    MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside by Burghardt Wittig, Manuel Schmidt, Werner Scheithauer, Hans‐Joachim Schmoll

    Published 2014
    Get full text
    Revisão
    Save to List
    Saved in:
  4. 4
    HER 2/neu protein expression in colorectal cancer

    HER 2/neu protein expression in colorectal cancer by B. Schuell, Thomas Gruenberger, Werner Scheithauer, Ch. Zielinski, Fritz Wrba

    Published 2006
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer.

    Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. by Werner Scheithauer, Harald Rosén, Gabriela Kornek, Christian Sebesta, D. Depisch

    Published 1993
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Answering Patients' Needs: Oral Alternatives to Intravenous Therapy

    Answering Patients' Needs: Oral Alternatives to Intravenous Therapy by Markus Borner, Werner Scheithauer, Chris Twelves, Jean A. Maroun, H. Wilke

    Published 2001
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  7. 7
    A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid

    A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid by Markus Kieler, Matthias Unseld, Daniela Bianconi, Werner Scheithauer, Gerald W. Prager

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases

    Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases by Birgit Gruenberger, Werner Scheithauer, Robert Punzengruber, Christoph Zielinski, Dietmar Tamandl, Thomas Gruenberger

    Published 2008
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Bevacizumab, Capecitabine, and Oxaliplatin As Neoadjuvant Therapy for Patients With Potentially Curable Metastatic Colorectal Cancer

    Bevacizumab, Capecitabine, and Oxaliplatin As Neoadjuvant Therapy for Patients With Potentially Curable Metastatic Colorectal Cancer by B. Gruenberger, Dietmar Tamandl, Johannes Schueller, Werner Scheithauer, Christoph Zielinski, Friedrich Herbst, Thomas Gruenberger

    Published 2008
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Mitomycin C in combination with capecitabine or biweeklyhigh-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial

    Mitomycin C in combination with capecitabine or biweeklyhigh-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial by Gabriela Kornek, B. Schuell, Friedrich Laengle, Thomas Gruenberger, M. Penz, K. Karall, D. Depisch, Fritz Lang, Werner Scheithauer

    Published 2004
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab‐based treatment response in metastatic colorectal cancer

    Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab‐based treatment response in metastatic colorectal cancer by Gerald W. Prager, Kira Braemswig, Alexandra Martel, Matthias Unseld, Georg Heinze, Thomas Brodowicz, Werner Scheithauer, Gabriela Kornek, Christoph Zielinski

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study

    Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study by Boris Dickmann, Jonas Ahlbrecht, Cihan Ay, Daniela Dunkler, J. Thaler, Werner Scheithauer, Peter Quehenberger, C. C. Zielinski, Ingrid Pabinger

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Thrombosis risk and survival in cancer patients with elevated C‐reactive protein

    Thrombosis risk and survival in cancer patients with elevated C‐reactive protein by R. Kanz, Thomas Vukovich, Rainer Vormittag, Daniela Dunkler, Cihan Ay, J. Thaler, Johanna Haselböck, Werner Scheithauer, Christoph Zielinski, Ingrid Pabinger

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer

    Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer by M. Penz, Gabriela Kornek, Markus Raderer, H. Ulrich-Pur, Wolfgang Fiebiger, A. Lenauer, D. Depisch, G. Krauss, Bruno Schneeweiß, Werner Scheithauer

    Published 2001
    Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial

    Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemothera... by Hans‐Joachim Schmoll, Burghardt Wittig, Dirk Arnold, Jorge Riera‐Knorrenschild, D. Nitsche, Hendrik Kroening, Frank Mayer, Johannes Andel, Reinhard Ziebermayr, Werner Scheithauer

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results

    XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results by J Cassidy, Stephen Clarke, Eduardo Díaz‐Rubio, Werner Scheithauer, Arié Figer, Ralph Wong, Sheryl Koski, Karen Rittweger, Frank Gilberg, Leonard B. Saltz

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy

    Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of... by Chris Twelves, Werner Scheithauer, J. McKendrick, Jean‐François Seitz, Guy van Hazel, A. Wong, Eduardo Díaz‐Rubio, Frank Gilberg, J Cassidy

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma

    Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma by H. Ulrich-Pur, Markus Raderer, Gabriela Kornek, B. Schüll, Katharina Schmid, K. Haider, W. Kwasny, D. Depisch, Bruno Schneeweiß, Fritz Lang, Werner Scheithauer

    Published 2003
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial

    Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial by Werner Scheithauer, B. Schüll, H. Ulrich-Pur, Katharina Schmid, Markus Raderer, K. Haider, W. Kwasny, D. Depisch, Bruno Schneeweiß, Friedrich Lang, Gabriela Kornek

    Published 2002
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Vasoactive Intestinal Peptide-Receptor Imaging for the Localization of Intestinal Adenocarcinomas and Endocrine Tumors

    Vasoactive Intestinal Peptide-Receptor Imaging for the Localization of Intestinal Adenocarcinomas and Endocrine Tumors by Irene Virgolini, Markus Raderer, Amir Kurtaran, P. Angelberger, S. Banyai, Qiong Yang, Shuren Li, Martin Banyai, Johann Pidlich, Bruno Niederle, Werner Scheithauer, Peter Valent

    Published 1994
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: